LEHVOSS Italia Srl is pleased to announce that we have reached an agreement for the exclusive distribution of SEQENS Cosmetics active ingredients for the Italian Personal Care market.
This partnership is part of LEHVOSS Personal Care's strategy of expanding the offer of natural ingredients that comply with the highest quality and regulatory standards. LEHVOSS Italia is excited about the new collaboration with SEQENS Cosmetics and to provide its customers with a broad portfolio of assets alongside exceptional technical and marketing support.
The distribution agreement with LEHVOSS Italia ensures SEQENS Cosmetics to enter in the Italian market with a partner appreciated and recognized by operators in the cosmetic sector with the aim of spreading its presence in the world of cosmetics and dermocosmetics.
SEQENS Group, founded in 2003 as a manufacturing company of pharmaceutical active ingredients, has a global presence, over 3000 employees and 7 Research and Development centers. The two main business areas of the group are pharmaceutical solutions and specialties. SEQENS Cosmetics has capitalized on its expertise in the pharmaceutical field, developing an offer of innovative active ingredients dedicated to the cosmetic market. Thanks to the collaboration with experienced researchers in different areas of interest and over 100 scientists at the service of the innovation process, SEQENS Cosmetics transforms the most recent scientific discoveries into cutting-edge natural ingredients, in line with market trends, sustainable, rigorously tested.
For more information: www.seqens.com
LEHVOSS Italia is the subsidiary of Lehmann & Voss & Co, a company based in Hamburg, Germany, operating in the sale of chemical and mineral specialties for the industrial and Life Science sectors. In Italy LEHVOSS offers to its customer a wide range of innovative specialties in the cosmetic sector thanks to exclusive agreements with international manufacturers, but also with small specialists producing unique and technologically advanced products.